A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Clinical trial NCT04782258 · RECRUITING
Trial details
- NCT number
- NCT04782258
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-23
- Primary completion
- 2028-07-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.